Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 10:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 180 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Heart Hypertrophy Clear all
Completed No phase listed Observational Accepts healthy volunteers

Family Studies of Inherited Heart Disease

NCT00001225
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
5,880 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1987 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 22, 2026, 10:10 PM EDT
Completed No phase listed Observational

Signs and Symptoms of Genetic Abnormalities Linked to Inherited Heart Disease

NCT00001881
View directory record Official record
Conditions
Cardiomyopathy, Hypertrophic, Familial
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
9,999 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 22, 2026, 10:10 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis

NCT06034405
View directory record Official record
Conditions
Lumbar Spinal Stenosis, Cardiac Amyloidosis, ATTR Amyloidosis Wild Type, ATTR Gene Mutation, ATTRV122I Amyloidosis, Cardiomyopathy, Hypertrophic
Interventions
Tc99-PYP or Tc99-HDMP Scan
Diagnostic Test
Lead sponsor
Columbia University
Other
Eligibility
50 Years and older
Enrollment
1,663 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
6
States / cities
Beverly Hills, California • Boston, Massachusetts • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 22, 2026, 10:10 PM EDT
Recruiting Phase 1Phase 2 Interventional

ATR 1072 in Participants With PRKAG2 Syndrome

NCT07738107
View directory record Official record
Conditions
Cardiac Glycogenosis, Cardiomyopathy, Hypertrophic, Wolff-Parkinson-White Syndrome
Interventions
ATR 1072
Drug
Lead sponsor
Atrium Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 22, 2026, 10:10 PM EDT
Recruiting Phase 4 Interventional

Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy

NCT07600177
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy (HCM)
Interventions
Aficamten
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Kansas City, Missouri • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 22, 2026, 10:10 PM EDT
Recruiting No phase listed Observational

Cardiovascular Multimodality Imaging Study

NCT06610019
View directory record Official record
Conditions
Non-ischemic Cardiomyopathy, Cardiomyopathies, Hypertrophic Cardiomyopathy, Right Ventricular Arrhythmogenic Cardiomyopathy, Cardiac Amyloidosis, Anderson Fabry Disease, Sarcoidosis, Cancer Therapy-related Cardiac Dysfunction, Ventricular Arrythmia, Heart Failure
Interventions
Not listed
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 22, 2026, 10:10 PM EDT
Completed Not applicable Interventional

Vitamin D Therapy to Reduce Cardiac Damage Among Vulnerable Hypertensive Patients

NCT01360476
View directory record Official record
Conditions
Hypertension, Left Ventricular Hypertrophy
Interventions
cholecalciferol (Vitamin D), Placebo
Dietary Supplement
Lead sponsor
Wayne State University
Other
Eligibility
30 Years to 74 Years
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 9, 2015 · Synced Oct 22, 2026, 10:10 PM EDT
Completed No phase listed Observational

FGF23 and Angiotensin-(1-7) in Hypophosphatemia (GAP)

NCT03489993
View directory record Official record
Conditions
Hypophosphatemia, X-linked Hypophosphatemia, Renin-angiotensin System, Left Ventricular Hypertrophy
Interventions
Ang II and Ang-(1-7), FGF23 and klotho
Diagnostic Test
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
2 Years to 24 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 5, 2022 · Synced Oct 22, 2026, 10:10 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Pediatric Primary Hypertension and the Renin-Angiotensin System (PHRAS)

NCT03310684
View directory record Official record
Conditions
Pediatric Disorder, Pediatric Obesity, Primary Hypertension
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
5 Years to 17 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 28, 2025 · Synced Oct 22, 2026, 10:10 PM EDT
Terminated Phase 2 Interventional Results available

Open-Label Study of Perhexiline in Patients With Hypertrophic Cardiomyopathy and Moderate to Severe Heart Failure

NCT02862600
View directory record Official record
Conditions
Cardiomyopathy, Hypertrophic, Cardiomyopathy, Hypertrophic, Familial
Interventions
Perhexiline, Use of bioanalytical assay to monitor plasma levels of perhexiline
Drug · Device
Lead sponsor
Heart Metabolics Limited
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
11
States / cities
Stanford, California • Indianapolis, Indiana • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2017 · Synced Oct 22, 2026, 10:10 PM EDT
Terminated No phase listed Observational

A Cardiac Disease Quality of Life Study

NCT04080492
View directory record Official record
Conditions
Hypertrophic Obstructive Cardiomyopathy, Thoracic Aortic Dilatation, Heart Disease Caused by Ionising Radiation, Quality of Life
Interventions
QOL Survey
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
380 participants
Timeline
2019 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 22, 2026, 10:10 PM EDT
Enrolling by invitation Phase 2Phase 3 Interventional

Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM

NCT04848506
View directory record Official record
Conditions
Symptomatic Hypertrophic Cardiomyopathy (HCM)
Interventions
Aficamten (5 - 20 mg)
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years to 85 Years
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
57
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 22, 2026, 10:10 PM EDT
Recruiting Phase 2 Interventional

A Gene Therapy Study of RP-A501 in Male Patients With Danon Disease

NCT06092034
View directory record Official record
Conditions
Danon Disease
Interventions
RP-A501
Genetic
Lead sponsor
Rocket Pharmaceuticals Inc.
Industry
Eligibility
8 Years and older · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
3
States / cities
La Jolla, California • Boston, Massachusetts • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 22, 2026, 10:10 PM EDT
Terminated Phase 3 Interventional Results available

The PRIMO II Study: Paricalcitol Injection Benefits in Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease (CKD) Stage 5

NCT00616902
View directory record Official record
Conditions
Chronic Kidney Disease (CKD) Stage 5, Hypertrophy, Left Ventricular
Interventions
paricalcitol injection 4 mcg/mL, Placebo Injection 4 mcg/mL
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
29
States / cities
Phoenix, Arizona • Tempe, Arizona • Bakersfield, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2012 · Synced Oct 22, 2026, 10:10 PM EDT
Recruiting Phase 1Phase 2 Interventional

Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM

NCT05836259
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy
Interventions
TN-201
Genetic
Lead sponsor
Tenaya Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
10
States / cities
La Jolla, California • San Francisco, California • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 22, 2026, 10:10 PM EDT
Completed Not applicable Interventional Results available

PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - Nested Registry 3/Valve-in-Valve

NCT03225001
View directory record Official record
Conditions
Aortic Stenosis, Cardiomyopathy, Hypertrophic
Interventions
Edwards SAPIEN XT transcatheter valve, Model 9300TFX
Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
Not listed
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
46
States / cities
La Jolla, California • Los Angeles, California • Sacramento, California + 39 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Oct 22, 2026, 10:10 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Association of Insulin Resistance and FGF21 on Cardiac Function in Pediatric Dilated Cardiomyopathy

NCT04222101
View directory record Official record
Conditions
Cardiomyopathy, Dilated, Cardiomyopathy, Hypertrophic, Insulin Resistance
Interventions
Oral glucose tolerance test
Diagnostic Test
Lead sponsor
Le Bonheur Children's Hospital
Other
Eligibility
13 Years to 18 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 20, 2021 · Synced Oct 22, 2026, 10:10 PM EDT
Completed Not applicable Interventional Results available

Study of Exercise Training in Hypertrophic Cardiomyopathy

NCT01127061
View directory record Official record
Conditions
Cardiomyopathy, Hypertrophic
Interventions
Exercise training
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 80 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
Stanford, California • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 22, 2026, 10:10 PM EDT
Completed Phase 2 Interventional

Studying the Effectiveness of Pacemaker Therapy in Children Who Have Thickened Heart Muscle

NCT00001960
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy
Interventions
Pacemaker therapy
Device
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 22, 2026, 10:10 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Human Experimental Models of Pain (HEMP)

NCT07549490
View directory record Official record
Conditions
Acute Pain
Interventions
Placebo, Naproxen, Pregabalin
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 100 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 22, 2026, 10:10 PM EDT
Completed Phase 2 Interventional Results available

Effect of Losartan in Patients With Nonobstructive Hypertrophic Cardiomyopathy

NCT01150461
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy
Interventions
losartan, placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 5, 2013 · Synced Oct 22, 2026, 10:10 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Derivation of Human Induced Pluripotent Stem (iPS) Cells to Heritable Cardiac Arrhythmias

NCT02413450
View directory record Official record
Conditions
Inherited Cardiac Arrythmias, Long QT Syndrome (LQTS), Brugada Syndrome (BrS), Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT), Early Repolarization Syndrome (ERS), Arrhythmogenic Cardiomyopathy (AC, ARVD/C), Hypertrophic Cardiomyopathy (HCM), Dilated Cardiomyopathy (DCM), Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy), Normal Control Subjects
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2031
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 22, 2026, 10:10 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Imaging Histone Deacetylase in the Heart

NCT03549559
View directory record Official record
Conditions
Heart Failure With Normal Ejection Fraction, Left Ventricular Hypertrophy, Aortic Valve Stenosis, Diabetes
Interventions
11C-Martinostat, PET-MRI
Drug · Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 22, 2026, 10:10 PM EDT
Completed Phase 2 Interventional

Cyclosporine A to Treat Hypertrophic Cardiomyopathy (HCM)

NCT00001965
View directory record Official record
Conditions
Cardiomyopathy, Hypertrophic, Heart Hypertrophy
Interventions
Cyclosporine A
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 22, 2026, 10:10 PM EDT